New York State Common Retirement Fund Sells 470 Shares of Novo Nordisk A/S (NYSE:NVO)

New York State Common Retirement Fund trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 0.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 58,436 shares of the company’s stock after selling 470 shares during the period. New York State Common Retirement Fund’s holdings in Novo Nordisk A/S were worth $6,045,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Pacific Center for Financial Services boosted its position in Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the last quarter. Bell Investment Advisors Inc raised its holdings in Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the last quarter. CNB Bank bought a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $26,000. Citizens National Bank Trust Department raised its stake in shares of Novo Nordisk A/S by 100.0% during the third quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock worth $27,000 after buying an additional 150 shares during the last quarter. Finally, Tyler Stone Wealth Management boosted its stake in Novo Nordisk A/S by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after acquiring an additional 146 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 0.8 %

NYSE:NVO opened at $123.08 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The business’s 50-day simple moving average is $127.21 and its 200-day simple moving average is $112.77. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The stock has a market capitalization of $552.33 billion, a PE ratio of 45.50, a price-to-earnings-growth ratio of 2.16 and a beta of 0.43.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. Sell-side analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on NVO shares. UBS Group started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating for the company. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price on the stock. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.